Single Cell Sequencing Analysis of Thymoma

• Sponsor: Zhejiang Cancer Hospital (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT04162691
• Collaborator: (none)
• Enrollment: 10
• Location: 1
• Anticipated Duration (Months): 18.8
• Patients Per Site Per Month: 0.5

Study Details

Study Description

Brief Summary

The purpose of this study is to understand how genetics play a role in thymoma. Intratumoral heterogeneity is among the greatest challenges in precision cancer therapy. However, developments in high-throughput single-cell RNA sequencing (scRNA-seq) may now provide the statistical power to dissect the diverse cellular populations of tumors. This study aims to find out how it affects genetic and protein expression in patients with malignant thymoma, compared to Benign thymoma, at a single-cell level using a flow cytometry and RNA-sequencing protocol.

Condition or Disease	Intervention/Treatment	Phase
Thymoma	Diagnostic Test: Tissue

Study Design

• Study Type: Observational
• Anticipated Enrollment: 10 participants
• Observational Model: Case-Control
• Time Perspective: Prospective
• Official Title: Single Cell Sequencing Analysis of Thymoma
• Actual Study Start Date: Jun 6, 2020
• Actual Primary Completion Date: Jun 1, 2021
• Anticipated Study Completion Date: Dec 31, 2021

Arms and Interventions

Arm	Intervention/Treatment
Malignant thymoma	Diagnostic Test: Tissue; Four 4-5 mm tissues of the thymoma
Benign thymoma	Diagnostic Test: Tissue; Four 4-5 mm tissues of the thymoma

Outcome Measures

Primary Outcome Measures

1. Determination of cell population from thymoma [through study completion, an average of 1 year]

   The genes expression and the cell population

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Patients diagnosed with thymoma

• Ability to provide written consent and comply with the protocol

• At least 18 years of age

Exclusion Criteria:

• Patients undergoing thymoma treatment

• Patients with previous malignancy

• Known HIV positive status.

• Evidence of abnormality of any immune cell population from a drug-induced or genetic cause.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	ZHAO AN	Hangzhou		China	310022

Sponsors and Collaborators

• Zhejiang Cancer Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: ZHAO An, Principal Investigator, Zhejiang Cancer Hospital
• ClinicalTrials.gov Identifier: NCT04162691
• Other Study ID Numbers: SCS-001
• First Posted: Nov 14, 2019
• Last Update Posted: Jun 3, 2021
• Last Verified: Jun 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Thymoma; Thymus Neoplasms

Study Results

No Results Posted as of Jun 3, 2021